Attenuation of the 'white-coat effect' by antihypertensive treatment and regression of target organ damage

Hypertension

Volumn 35, Issue 2, 2000, Pages 614-620

  Parati, Gianfranco ^b   Ulian, Luisa ^b   Sampieri, Lorena ^c   Palatini, Paolo ^c   Villani, Alessandra ^b   Vanasia, Alessandro ^b   Mancia, Giuseppe ^a,b  

^a SAN GERARDO HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c NONE

Author keywords

Antihypertensive agents; Blood pressure; Hypertension, white coat

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LISINOPRIL;

ADULT; AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; WHITE COAT HYPERTENSION;

EID: 0033983955     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.2.614     Document Type: Article

References (38)

1. Floras JS, Jones JV, Hassan MD, Osikowska B, Sever PS, Sleight P. Cuff and ambulatory blood pressure in subjects with essential hypertension. Lancet. 1981;1:107-109.
2. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24 hour blood pressure mean and variability to severity of target organ damage in hypertension. Hypertension. 1987;5:93-98.
3. Pickering TG, James GD, Harshfield GA, Blank S, Laragh JH. How common is white-coat hypertension? JAMA 1988;259:225-228.
4. Gosse P, Bougaleb M, Egloff P, Lemetayer P, Clementy J. Clinical significance of white-coat hypertension. J Hypertens. 1994;12(suppl 8):S43-S47.
5. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci G, Reboldi G. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1984;24:793-801.
6. Kuvajima I, Suzuki J, Fujisawa A, Kuramoto K. Is white-coat hypertension innocent? Structure and function of the heart in the elderly. Hypertension. 1993;22:826-831.
7. Julius S, Mejia A, Jones JC, Krause L, Schork N, Van De Ven C, Johnson E, Petrin J, Sekkarie MA, Kjeldsen SE, Schmouder R, Gupta R, Ferraro J, Nazaro P, Weissfeld J. White-coat versus sustained borderline hypertension in Tecumseh, Michigan. Hypertension. 1990;16:617-623.
8. Cardillo C, De Felice F, Campia U. Psychophysiological reactivity and cardiac end-organ changes in white-coat hypertension. Hypertension 1993;22:836-844.
9. Cerasola G, Cottone S, Nardi E, D'Ignoto G, Volpe V, Mulè G, Carollo C. White-coat hypertension and cardiovascular risk. J Cardiovasc Risk 1995;2:545-549.
10. Guidelines subcommittee of the WHO/ISH mild hypertension liaison committee. 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Hypertension 1993;22: 392-403.
11. Guidelines Subcommittee. World Health Organization/International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999;17:151-183.
12. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Porcellati C. Prognostic significance of the white coat effect. Hypertension. 1997;29:1218-1224.
13. Gosse P, Promax H, Durandet P, Clementy J. White coat hypertension: no harm for the heart. Hypertension. 1993;22:766-770.
14. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, Pessina A, Porcellati C, Salvetti A, Trimarco B, for the SAMPLE study group. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation. 1997;95:1464-1470.
15. Mancia G, Sega R, Bravi C, De Vito G, Valagussa G, Zanchetti A. Ambulatory blood pressure normality: results from the PAMELA study. Hypertension. 1995;13:1377-1390.
16. Groppelli A, Omboni S, Parati G, Mancia G. Evaluation of non-invasive blood pressure monitoring devices Spacelabs 90202 and 90207 versus resting and ambulatory 24 hour intra-arterial blood pressure. Hypertension. 1992;20:227-232.
17. Casadei R, Parati G, Pomidossi G, Groppelli A, Trazzi S, Di Rienzo M, Mancia G. 24-h blood pressure monitoring: evaluation of Spacelabs 5300 monitor by comparison with intra-arterial blood pressure recording in ambulant subjects. J Hypertens. 1988;6:797-803.
18. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation. 1977;55:613-618.
19. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens. 1989;7:1325-1350.
20. SPSS Professional Statistics 7.5: User's Manual. Chicago, Ill: SPSS Inc; 1997.
21. Myers MG, Reeves RA. White-coat phenomenon in patients receiving anti-hypertensive therapy. Am J Hypertens. 1991;4:844-884.
22. Parati G, Omboni S, Mancia G. Difference between office and ambulatory blood pressure and response to anti-hypertensive treatment. J Hypertens. 1996;14:791-797.
23. Parati G, Pomidossi G, Casadei R, Mancia G. Lack of alerting reactions to intermittent cuff inflation during non-invasive blood pressure monitoring. Hypertension. 1985;7:597-601.
24. Mancia G, Bertinieri G, Grassi G, Parati G, Pomidossi G, Ferrari A, Gregorini L, Zanchetti A. Effects of blood pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet. 1983;2: 695-698.
25. Parati G, Omboni S, Staessen J, Thijs L, Fagard R, Mancia G. Limitations of the difference between clinic and daytime blood pressure as a surrogate measure of the "white-coat effect." J Hypertens. 1998;16:23-29.
26. Parati G, Ulian L, Santucciu C, Omboni S, Mancia G. The difference between clinic and daytime blood pressure is not a measure of the "white-coat effect." Hypertension. 1998;31:1185-1189.
27. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
28. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
29. Muiesan ML, Salvetti M, Rizzoni R, Castellano M, Donate F, Agabiti Rosei E. Association of changes in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13: 1091-1095.
30. Stark G, Stark U, Nagl S, Klein W, Pilger E, Tritthart HA. Acute effects of the ACE inhibitor lisinopril on cardiac electrophysiological parameters of isolated guinea pig hearts. Clin Cardiol. 1991;14:579-582.
31. Rials SJ, Wu Y, Ford N, Pauletto FJ, Abramson SV, Rubin AM, Marinchak RA, Kowey PR. Effect of LVH and its regression on ventricular electrophysiology and vulnerability to inducible arrhythmia in the feline heart. Circulation. 1995;91:426-430.
32. Kohya T, Yokoshiki H, Toshe N, Kanno M, Nakaya H, Saito H, Kitabatake A. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias: beneficial effect of angiotensin II blockade. Circ Res. 1995;76:892-899.
33. Yurenev AP, Dyakonova HG, Novikov ID, Vitols A, Pahl L, Haynemann G, Wallrabe D, Tsifkova R, Romanovska L, Niderle P. Management of essential hypertension in patients with different groups of left ventricular hypertrophy: a multicenter trial. Am J Hypertens. 1992;5:1825-1835.
34. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial change in subjects with electrocardiographjc left ventricular hypertrophy. Circulation. 1995;90:1786-1793.
35. Koren MJ, Savage DD, Casale PN, Laragh JH, Devereux RB. Changes in left ventricular mass predict risk in essential hypertension. Circulation 1990;82(suppl III):20. Abstract.
36. Grassi G, Giannattasio C, Cleroux J, Cuspidi C, Sampieri L, Bolla GB, Mancia G. Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension. Hypertension 1988;12: 227-237.
37. Strauer BE. Regression of myocardial and coronary vascular hypertrophy in hypertensive heart disease. J Cardiovasc Pharmacol. 1988;12(suppl 4):S45-S54.
38. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54.